This page describes patient-reported outcome measures in urticaria.

Urticaria control test (UCT)1

Monthly

The UCT covers the following 4 domains:

 

  • Validated and specifically designed for chronic urticaria
  • Self-administered, retrospective (past 4 weeks) 4-item questionnaire
  • Each answer is scored ranging from 0 to 4
  • The summed score ranges from 0: no control to 16: full control

 

Urticaria activity score (UAS7)*

Daily

A method for assessing disease severity

  • Tools are available for angioedema-only patients2    
  • Patient scores their number of hives (0 to 3)** and pruritus severity (0 to 3)† each day for 7 days2
  • Maximum weekly score is 42 – a higher score corresponds to more severe disease   
  • Severe CSU has a UAS7 score of 28–423

*Included in the NICE guidance as an example of objective assessment of disease severity.
**Scoring from 0 (none) to 3 (intense).

 

Dermatology Life Quality Index (DLQI)4

Weekly

The DLQI is a simple, validated questionnaire used to evaluate health-related quality of life in patients with skin diseases.

  •     It consists of 10 questions comprising 6 domains: 

 

  • The effect of the disease on each domain is scored from 0 (not at all) to 3 (very much) for each question, giving a total score of between 0 and 30
  • Higher DLQI score corresponds to greater impairment on quality of life

As part of our mission to be as environmentally friendly as possible, we provide our resources in electronic form.

These materials should not be printed by healthcare professionals.

 

PATIENT-REPORTED OUTCOMES GUIDELINE

The patient-reported outcomes guideline presents patient-reported outcomes for healthcare professionals to use with patients with CSU; these outcomes include the UCT, UAS7 and DLQI.

View

 

CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; UAS7, uticaria activity score at seven days; UCT, urticaria control test.

References     

  1. Moestrup K et al. Int J Dermatol 2017; 56:1342–1348.
  2. Zuberbier T et al. Allergy 2018;73(7):1393–1414.
  3. Stull D et al. EAACI 2014, abstract 826.
  4. Finlay AY et al. Clin Exp Dermatol 1994;19(3):210–216.
XSU20-C017 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]